Oncotelic Therapeutics, Inc today announced that it has submitted a clinical study protocol to the US Food and Drug Administration (“FDA”) for the initiation of a Phase 2b/3 Trial (designated “P201") for OT-101, the Company’s transforming growth factor beta 2 (“TGF-β2”) inhibitor, as a treatment for metastatic pancreatic cancer.
January 25, 2023
· 7 min read